Application of Hsp70 inhibitors decreases the brain tumor cell migratory activity. A–C, mHsp70 expression in nontreated C6, T98G, U251 cell lines and cells incubated with 1 μmol/L PES or 50 nmol/L JG98 inhibitors. A, Confocal microscopy images of C6, T98G, U251. DAPI was applied for nucleus staining (blue). FITC-anti-Hsp70 antibody was used for detecting mHsp70 on the plasma membrane (green). Scale bars, 50 μm. B, Mean signal intensity of FITC-anti-Hsp70 antibody in nontreated C6, T98G, U251 cell lines and cells incubated with 1 μmol/L PES or 50 nmol/L JG98 inhibitors observed by confocal microscopy (nimages ≥ 20). C, Mean fluorescence intensity of FITC-anti-Hsp70 antibody in arbitrary units measured by flow cytometry. D, Comparison of mean speed, straightness, and sinuosity of sorted nontreated and treated C6, T98G, and U251 cells with 1 μmol/L PES or 50 nmol/L JG98 (ntracks ≥ 46). Data are presented as median ± 95% CI. Significant differences identified by the Wilcoxon test are shown as *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.
No takes yet. Share an insight, caveat, or question.
Shevtsov et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: